The cell lines used in the studies include triple negative breast cancer cell BT-20 cells, HER-2 overexpressing MDA-MB-453 cells, luminal MCF7 cells, and Hs578Bst which have severe resistance against DOX. The gene discussed is ERBB2; the disease is triple-negative breast carcinoma.